*CURRICULUM VITAE*

**EDUCATION:**

2003-2005 Veterans’ Affairs/Cedars-Sinai Healthcare Center

Los Angeles, CA

Nephrology Fellowship

2000-2003 UCLA/Veterans’ Affairs Healthcare System

Los Angeles, CA

Internship and Residency in Internal Medicine

1996-2000 Oregon Health Science University

Portland, OR

Doctor of Medicine

1994 University of California

Los Angeles, CA

Emergency Medical Technician

1990-1994 University of Southern California

Los Angeles, CA

Bachelor of Science-Exercise Science and Kinesiology

**CERTIFICATIONS:**

Board Certified in Nephrology

Medical Board of California Physician License

**HONORS AND AWARDS:**

Laurel Merit Academic Scholarship – Oregon Health Sciences University

Alpha Epsilon Delta National Premedical Honors Society

**PROFESSIONAL MEMBERSHIPS:**

National Kidney Foundation

American Society of Nephrology

Renal Physicians’ Association

American Medical Association

American College of Physicians – American Society of Internal Medicine

**VOLUNTEER EXPERIENCE:**

Principles of Clinical Medicine – Oregon Health Sciences University

Chairperson of the Multicultural Student Affairs Office – Oregon Health Science

University.

**ADDITIONAL PROFESSIONAL ACTIVITIES:**

Attending physician at the West Los Angeles Veterans’ Affairs Emergency Department working with and educating interns and residents.

**CLINICAL COMPETENCY:**

Intravenous dialysis catheter placements, kidney biopsies.

**RESEARCH:**

Identifying the prevalence of Chronic Kidney Disease in the Southern California VA System and clinical practice adherence to the established guidelines set forth by Veterans’ Health Administration and the National Kidney Foundation.

Research Assistant for Colon Cancer Epidemiologic and Genetic Study - University of Southern California.

**CLINICAL STUDY LOCATION:**

Tower Nephrology Medical Group, Los Angeles, CA

DaVita Beverly Hills Dialysis, Los Angeles, CA

DaVita Crescent Heights Dialysis, Los Angeles, CA

**CLINICAL STUDIES:**

\* 2015 ICH Good Clinical Practice for Clinical Trial Sites (**Certificates**)

Sub Investigator 2015 A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi- Center Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dihydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes (PIONEER)

Sub Investigator 2015 A Multicenter Single-arm Extension Study to Describe the Long-  
 term Safety of AMG 416 in the Treatment of Secondary   
 Hyperparathyroidism in Subjects With Chronic Kidney Disease   
 on Hemodialysis

Sub Investigator 2015 A Phase 3, Randomized, Double-Blind, Placebo Controlled Study

Of the Efficacy and Safety of Roxadustat (FG-4592) for the

Treatment of Anemia in Chronic Kidney Disease Patients not on

Dialysis

Sub Investigator 2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV,   
 open Label, Multicenter Trial, with MRI Substudy, of Repeated   
 Doses Ferumoxytol Compared with Iron Sucrose for the   
 Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney   
 Disease (CDK) Patients on Hemodialysis   
  
Sub- Investigator 2014 A Multicenter Single-arm Extention Study to Describe the Long-  
 term Efficacy and Safety of AMG 416 in the Treatment of   
 Secondary Hyperparathroidism in Subjects With Chronic Kidney   
 Disease on Hemodialysis

Sub- Investigator 2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis.

Principal Investigator 2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.

Sub- Investigator 2013 Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.

Principal Investigator 2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137

Principal Investigator 2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy

Sub-Investigator 2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502

(ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis

Sub- Investigator 2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease

and type 2 diabetes: The occurrence of renal events (Beacon)

Sub-Investigator 2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study

Sub-Investigator 2010 A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Sub-Investigator 2010 Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

Sub-Investigator 2009 A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor

Sub-Investigator 2008 Phase 2, randomized, double-blind, placebo-controlled, parallel group,

fixed dose study of AMG 223 in subjects with chronic kidney disease on

hemodialysis with hyperphosphatemia.

Sub-Investigator 2007 A Phase III, Randomized, active-controlled, open-label, multi-center

study of the safety and efficacy of AF37702 injection for the

maintenance treatment of anemia in hemodialysis patients previously

treated with epoetin

Sub-Investigator 2007 Outcome trial evaluating the efficacy and safety of Norditropin® on

adult patients on chronic haemodialysis

Sub-Investigator 2007 A Phase IV, Long-term, Observational Safety Study in End Stage Renal

Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator 2007 A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and

Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in

Peritoneal Dialysis patients who self inject or receive in-center

Injections.

Sub-Investigator 2007 Prospective, Open Label, Randomized multicenter study to demonstrate

the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin

control in patients transitioning from chronic kidney disease. Stage 4

through dialysis.

Sub-Investigator 2007 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of

AST-120 for Prevention of Chronic kidney Disease Progression in

Patients with Moderate to Severe Chronic Kidney Disease.

Sub-Investigator 2007 A Randomized, Open-Label, multicenter study Epoetin Alfa comparing

two extended-dosing regimens, Once-every-Two-Weeks, and Once-

Every-Four-Weeks, with the Once-Weekly dosing regimen for

maintenance treatment in anemic subjects with chronic kidney disease.

Sub-Investigator 2007 An Open Label Randomized, Paralled-Group, Clinical Endpoint

Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

Sub-Investigator 2006 Arandomized, double blind, placebo controlled, parallel group

study to assess the effect of the endothelin receptor antagonist

avosentan on time to doubling of serum creatinine, end stage

renal disease or death in patients with type 2 diabetes mellitus

and diabetic nephropathy.

Sub-Investigator 2006 Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular

Events.

Sub-Investigator 2006 A Phase III Study if the Safety and Efficacy of Ferumoxytol

(compared with oral iron) as an Iron Replacement Therapy in

Chronic Kidney Disease Patients not on Dialysis.

Sub-Investigator 2005 An Open-Label, Single-Arm Study to Assess the Safety of

Darbepoetin Alfa Manufactured by a Serum Free

Bioreactor Technology in Subjects with Chronic Kidney Disease